Related Experiment Video
Updated: Oct 4, 2025
Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
Published on: June 7, 2020
Assessing Estrogenic Activity of Classical Estrogen Receptor-Binding Compounds
Richard A Pepermans1, Eric R Prossnitz2,3,4
1Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Abstract:
The classical estrogen receptor α (ERα) has been a clinical therapeutic target for decades. ERα-targeted drugs have shown great clinical success, in particular as antagonists for the treatment of ERα-positive breast cancers. However, ERα-targeted agonists have also been clinically useful (e.g., for the treatment of osteoporosis). The breast cancer field is regularly identifying novel ERα-binding compounds with the goal of identifying new potential ERα-targeted therapeutics. To determine whether such newly identified ERα-binding compounds have clinical potential, it is important to characterize the estrogenic activity (i.e., both receptor-mediated agonism and/or antagonism) of these compounds. This chapter focuses on methods that allow determination of whether an ERα-binding compound acts as an agonist or antagonist of the receptor and whether the compound induces degradation of the receptor.
Insights
This study details methods for evaluating new estrogen receptor alpha (ERα)-binding compounds. It focuses on determining if these compounds act as agonists or antagonists, crucial for developing novel therapeutics.
Area of Science:
- Endocrinology
- Pharmacology
- Oncology
Background:
- Estrogen receptor alpha (ERα) is a key target for treating ERα-positive breast cancers and osteoporosis.
- Novel ERα-binding compounds are continually discovered, necessitating evaluation for therapeutic potential.
- Understanding a compound's estrogenic activity (agonism/antagonism) is vital for drug development.
Purpose of the Study:
- To outline methods for characterizing the estrogenic activity of ERα-binding compounds.
- To determine if novel compounds function as agonists or antagonists of ERα.
- To assess if compounds induce ERα degradation.
Main Methods:
- Focuses on experimental approaches to evaluate ERα-binding compounds.
- Describes assays to differentiate between ERα agonism and antagonism.
- Includes methods to detect ERα receptor degradation.
Main Results:
- Provides a framework for assessing the functional activity of ERα modulators.
- Enables classification of compounds based on their interaction with ERα.
- Facilitates the identification of potential therapeutic agents.
Conclusions:
- Characterizing ERα agonism, antagonism, and degradation is essential for novel therapeutic discovery.
- These methods are critical for advancing the development of ERα-targeted drugs.
- The study provides a guide for researchers in the field of ERα-targeted therapeutics.
More Related Videos
14:13Detecting Estrogenic Ligands in Personal Care Products using a Yeast Estrogen Screen Optimized for the Undergraduate Teaching Laboratory
Published on: January 1, 2018
09:07Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
